A short primer from @armykalsi on peptides as amino acid chains that carry signals between cells, plus a pitch for treating the whole body.
Recap by typeshit. Post by @armykalsi on Instagram.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Lilly Medical points to newly published results from a double-blind, placebo-controlled phase 3 study of its triple-hormone shot in people with diabetes.
Investseekers points to Fierce Pharma's refreshed chart showing how the two oral obesity pill launches from Novo Nordisk and Eli Lilly are tracking over time.
ETFDb lists the REX Peptide ETF among this week's new funds. It targets companies working on peptide drugs, supplements, cosmetics and devices.
Loading…